CA3232209A1 - Compositions and methods for treating patients with dementia due to alzheimer's disease with a combination of thc and melatonin - Google Patents
Compositions and methods for treating patients with dementia due to alzheimer's disease with a combination of thc and melatonin Download PDFInfo
- Publication number
- CA3232209A1 CA3232209A1 CA3232209A CA3232209A CA3232209A1 CA 3232209 A1 CA3232209 A1 CA 3232209A1 CA 3232209 A CA3232209 A CA 3232209A CA 3232209 A CA3232209 A CA 3232209A CA 3232209 A1 CA3232209 A1 CA 3232209A1
- Authority
- CA
- Canada
- Prior art keywords
- thc
- compound
- medicament
- compounds
- melatonin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245799P | 2021-09-17 | 2021-09-17 | |
| US63/245,799 | 2021-09-17 | ||
| PCT/US2022/076579 WO2023044433A1 (en) | 2021-09-17 | 2022-09-16 | Compositions and methods for treating patients with dementia due to alzheimer's disease with a combination of thc and melatonin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3232209A1 true CA3232209A1 (en) | 2023-03-23 |
Family
ID=83688895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3232209A Pending CA3232209A1 (en) | 2021-09-17 | 2022-09-16 | Compositions and methods for treating patients with dementia due to alzheimer's disease with a combination of thc and melatonin |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250275935A1 (https=) |
| EP (1) | EP4401717A1 (https=) |
| JP (1) | JP2024535871A (https=) |
| CA (1) | CA3232209A1 (https=) |
| CL (1) | CL2024000782A1 (https=) |
| CO (1) | CO2024004628A2 (https=) |
| PE (1) | PE20241236A1 (https=) |
| WO (1) | WO2023044433A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3773527A4 (en) | 2018-03-30 | 2022-04-13 | India Globalization Capital, Inc. | METHOD AND COMPOSITION FOR THE TREATMENT OF CNS DISEASES |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR44305E (fr) | 1933-12-09 | 1934-12-24 | Meaf Mach En Apparaten Fab Nv | Circuits de voie à rails sans potentiel ou portés au même potentiel |
| US11065225B1 (en) | 2015-07-30 | 2021-07-20 | University Of South Florida | Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's disease |
| EP3538122B1 (en) * | 2016-11-14 | 2025-03-26 | Farm To Farma, Inc. | Cannabinoid formulations and method of making the same |
| EP3582755A4 (en) * | 2017-02-15 | 2020-12-23 | Molecular Infusions, LLC | PREPARATIONS |
| WO2019036243A1 (en) * | 2017-08-16 | 2019-02-21 | Molecular Infusions, Llc | Formulations |
| US20200246404A1 (en) * | 2017-02-15 | 2020-08-06 | Molecular Infusions, Llc | Formulations |
| EP3773527A4 (en) | 2018-03-30 | 2022-04-13 | India Globalization Capital, Inc. | METHOD AND COMPOSITION FOR THE TREATMENT OF CNS DISEASES |
| WO2021011421A1 (en) * | 2019-07-12 | 2021-01-21 | University Of South Florida | Compositions and methods for treating alzheimers disease |
-
2022
- 2022-09-16 EP EP22786718.1A patent/EP4401717A1/en active Pending
- 2022-09-16 CA CA3232209A patent/CA3232209A1/en active Pending
- 2022-09-16 US US18/692,705 patent/US20250275935A1/en active Pending
- 2022-09-16 WO PCT/US2022/076579 patent/WO2023044433A1/en not_active Ceased
- 2022-09-16 PE PE2024000480A patent/PE20241236A1/es unknown
- 2022-09-16 JP JP2024517078A patent/JP2024535871A/ja active Pending
-
2024
- 2024-03-15 CL CL2024000782A patent/CL2024000782A1/es unknown
- 2024-04-12 CO CONC2024/0004628A patent/CO2024004628A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023044433A1 (en) | 2023-03-23 |
| PE20241236A1 (es) | 2024-06-19 |
| JP2024535871A (ja) | 2024-10-02 |
| CO2024004628A2 (es) | 2024-05-10 |
| US20250275935A1 (en) | 2025-09-04 |
| EP4401717A1 (en) | 2024-07-24 |
| CL2024000782A1 (es) | 2024-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10052339B2 (en) | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids | |
| Herrmann et al. | Current and emerging drug treatment options for Alzheimer’s disease: a systematic review | |
| CA2867891C (en) | App specific bace inhibitors (asbis) and uses thereof | |
| KR20220147636A (ko) | 칸나비디올 및 에버롤리무스에 의한 복합 결절성 경화증 치료 방법 | |
| US10117883B2 (en) | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids | |
| MX2007007038A (es) | Formulacion de dronabinol en temperatura ambiente. | |
| JP2001517617A (ja) | 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法 | |
| US11622937B2 (en) | Polyphenolic polymer to make water-insoluble molecules become water-soluble | |
| US20140243422A1 (en) | Methods of treating behavioral and psychiatric disorders | |
| US20200215022A1 (en) | Novel cannabinoid compositions and methods of treating pediatric epilepsy | |
| US20150265636A1 (en) | Compositions and methods for treating addiction | |
| Yasamineh et al. | Potential use of the cholesterol transfer inhibitor U18666A as a potent research tool for the study of cholesterol mechanisms in neurodegenerative disorders | |
| CA3232209A1 (en) | Compositions and methods for treating patients with dementia due to alzheimer's disease with a combination of thc and melatonin | |
| KR20200032759A (ko) | 신경정신계 장애의 치료를 위한 조성물 및 방법 | |
| CN102552135A (zh) | 制备维生素k1乳剂的方法和维生素k1乳剂 | |
| Sachs-Barrable et al. | The effect of two novel cholesterol-lowering agents, disodium ascorbyl phytostanol phosphate (DAPP) and nanostructured aluminosilicate (NSAS) on the expression and activity of P-glycoprotein within Caco-2 cells | |
| US20200268684A1 (en) | Composition for treating and preventing neurological diseases, neuroinflamation and alzheimer's disease | |
| CN121443298A (zh) | 用于治疗持续性脑震荡后症状的苯加兰他敏 | |
| Srivastav et al. | An investigation into Alzheimer's disease, its current treatments, biomarkers, and risk factors | |
| WO2020188569A1 (en) | Methods and compositions for preventing or treating weight gain caused by psychiatric drugs | |
| Bashir et al. | Emerging Trends in Therapeutic Potential of Curcumin in Alzheimer’s Disease | |
| Díaz Vélez | Pharmacokinetics of oral tetrahydrocannabinol and cannabidiol in humans: a systematic critical review | |
| WO2026088136A1 (en) | Methods of treating a neurodegenerative disease | |
| WO2023159277A1 (en) | Cannabinoid dosage form | |
| EA051671B1 (ru) | Ганаксолон для использования в лечении комплекса туберозного склероза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240830 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240830 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240830 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250911 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250911 |